Table 4.
Outcomes of 125 patients with more than 1 positive culture for nontuberculous mycobacteria from 2000 to 2012.
MABSC |
MAC |
Other NTM/co-infecteda |
||||
---|---|---|---|---|---|---|
2–4 pos | ≥ 5 pos | 2–4 pos | ≥ 5 pos | 2–4 pos | ≥ 5 pos | |
Number of patients | 23 | 34 | 17 | 19 | 16 | 16 |
Median duration of infection, y | 1 | 5 | 1 | 3 | 2 | 6 |
Received NTM treatment, n (%) b | 13/19 (68%) | 28/30 (93%) | 5/14 (36%) | 15/17 (88%) | 4/11 (36%) | 14/16 (88%) |
Cleared infection, n (%) c | 8/15 (53%) | 5/31 (16%) | 10/17 (59%) | 8/19 (42%) | 8/16 (50%) | 8/16 (50%) |
ESLD, all, n (%) | 5 (22%) | 9 (26%) | 1 (6%) | 4 (16%) | 3 (19%) | 2 (13%) |
ESLD judged NTM related, n (%) | 1 (4%) | 8 (24%) | 0 | 3 (16%) | 1 (6%) | 2 (13%) |
32 patients who had NTM species other than MABSC and MAC or combinations of more than one NTM species.
Data missing for 18 patients.
11 patients excluded due to too recent infection, MABSC = M. abscessus complex, MAC = M. avium complex, IQR = Interquartile range, ESLD = end stage lung disease, defined as death or lung transplantation during the study period.